Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses And Other Current Liabilities

Accrued Expenses And Other Current Liabilities

3 Months Ended

Mar. 31, 2020

Accrued Liabilities and Other Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities as of March 31, 2020 and December 31, 2019 consisted of the following:



	As of
	March 31, 2020		December 31, 2019
Research and development expenses	$	1,873,361	$	920,901
Compensation and benefits	1,413,014		1,591,964
General and administrative	1,035,454		120,056
Sales and marketing	207,950		360,016
Sales returns and allowances	1,361,410		2,284,175
Medicaid rebates	95,410		118,271
Other	207,606		244,869
Total accrued expenses and other current liabilities	$	6,194,205	$	5,640,252

During the first quarter of 2020, the Company and an executive entered into a Separation Agreement (the "Separation Agreement") in which the executive resigned his employment at the Company, effective June 30, 2020 (the "Termination Date"). Following the Termination Date and subject to the executive entering into a release at that time, the executive will receive continued payments of his base salary for a total of nine months, which resulted in an accrual of $0.3 million recognized in accrued expenses and other current liabilities on the Company's accompanying condensed consolidated balance sheet as of March 31, 2020 and is shown within the compensation and benefits line above. Additionally, the executive's unvested stock options as of his Termination Date will immediately vest and be exercisable until 90 days following the Termination Date and his outstanding Restricted Stock Units will immediately vest.